GW0742is a selective agonist of the peroxisome proliferator-activated receptor beta/delta (PPARβ/δ). It has been investigated for its potential therapeutic applications in various conditions, including metabolic disorders, inflammation, and cardiovascular diseases.
GW0742 has shown efficacy in preclinical studies, demonstrating anti-inflammatory, anti-diabetic, and cardioprotective effects. It has been studied for its role in improving insulin sensitivity, reducing hepatic steatosis, and mitigating endothelial dysfunction in obesity-related conditions. Additionally, GW0742 has been shown to enhance fatty acid oxidation (FAO) and modulate endothelial cell metabolism, supporting its potential in angiogenesis and tissue repair.
The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
| Other Names | GW 0742, GW-0742, {4-[({2-[3-Fluoro-4-(Trifluoromethyl)phenyl]-4-Methyl-1, 3-Thiazol-5-Yl}methyl)sulfanyl]-2-Methylphenoxy}acetic Acid |
|---|---|
| IUPAC Name | 2-[4-[[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1, 3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]acetic acid |
| CAS | 317318-84-6 |
| Molecular Weight | 471.5 |
| Molecular Formula | C21H17F4NO3S2 |
| SMILES | CC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=CC(=C(C=C3)C(F)(F)F)F)C)OCC(=O)O |